Global HER-2 Positive Breast Cancer Market 2015-2019
About HER-2 Positive Breast Cancer
Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.
TechNavio's analysts forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global HER-2 Positive Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, Global HER-2 Positive Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global HER-2 Positive Breast Cancer market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions
TechNavio Announces the Publication of its Research Report – Global HER-2 Positive Breast Cancer Market 2015-2019
TechNavio recognizes the following companies as the key players in the Global HER-2 Positive Breast Cancer Market: Celgene Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG and Sanofi SA.
Other Prominent Vendors in the market are: Actavis, Array BioPharma, Biocad, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, DARA BioSciences, EddingPharm, Eisai, Galena Biopharma, Halozyme Therapeutics, Hospira, Mylan, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Sun Pharmaceutical Industries, Synta Pharmaceuticals and Teva Pharmaceutical.
Commenting on the report, an analyst from TechNavio’s team said: “Increased public awareness is a key trend, which is expected to positively impact the growth of the market. Awareness and screening programs can help diagnose potential cases of breast cancer that would otherwise remain undetected till the late stages.”
According to the report, the increase in the prevalence of breast cancer is a major driver, which is expected to affect the overall market growth in the next five years. With the growing incidence of breast cancer, more and more people are opting for the treatment regimen.
Further, the report states that late-stage diagnosis and expensive screening techniques pose a challenge to the market and have a negative impact on the market growth. Expensive screening techniques like mammography screening lead to poor response from patients.
Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi, Actavis, Array BioPharma, Biocad, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb , Celltrion, Chugai Pharmaceutical, DARA BioSciences, EddingPharm , Eisai , GalenaBiopharma, Halozyme Therapeutics, Hospira , Mylan , Oncothyreon, Pfizer , ProStrakan, Puma Biotechnology, Sun Pharmaceutical Industries , Synta Pharmaceuticals, Teva Pharmaceutical
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook